|
Gabapentin enacarbil (Horizant (in USA), Regnite (in Japan), formerly known as XP-13512) is a prodrug for the anticonvulsant and analgesic drug gabapentin. It was designed for increased oral bioavailability over gabapentin, and human trials showed it to produce extended release of gabapentin with almost twice the overall bioavailability, especially when taken with a fatty meal. Gabapentin enacarbil has passed human clinical trials for the treatment of restless legs syndrome, and initial results have shown it to be well tolerated and reasonably effective. Gabapentin enacarbil was denied approval by the U.S. Food and Drug Administration (FDA) in February 2010, citing concerns about possible increased cancer risk shown by some animal studies. Similar concerns had been raised about gabapentin itself in the past, but were felt to be outweighed by its clinical utility as an anticonvulsant, whereas the treatment of restless legs syndrome was not seen to justify the same kind of risk.〔(GlaxoSmithKline/XenoPort: FDA setback halts gabapentin reformulations )〕 On April 6, 2011, Xenoport received FDA approval for Horizant (gabapentin enacarbil) for the treatment of moderate-to-severe restless legs syndrome.〔()〕 On June 7, 2012, FDA approved Horizant for the treatment of postherpetic neuralgia in adults. ==See also== * Atagabalin * 4-Methylpregabalin 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Gabapentin enacarbil」の詳細全文を読む スポンサード リンク
|